Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Senzime AB ( (SE:SEZI) ) is now available.
Senzime AB reported accelerated growth for the full year 2025, achieving more than 90% sales growth in constant currencies as it pushes toward profitability. The company improved its underlying gross margin, kept operating expenses in line with plan, and delivered a 16% improvement in EBITDA when excluding a write-down of older components, signaling stronger operational leverage in both the U.S. and other international markets.
The most recent analyst rating on (SE:SEZI) stock is a Sell with a SEK4.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime AB operates in the medical technology sector, focusing on monitoring solutions used in clinical settings. The company targets international markets, with a particular emphasis on expanding its presence in the U.S. and other key healthcare regions.
Average Trading Volume: 224,964
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK785.3M
See more data about SEZI stock on TipRanks’ Stock Analysis page.